Publishing research using ab205921? Please let us know so that we can cite the reference in this datasheet.
ab205921 has been referenced in 55 publications.
Tang YC et al.Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.Int J Oncol 52:127-138 (2018).
PubMed: 29115601
Amatatsu M et al.Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.Cancer Sci 109:814-820 (2018).
PubMed: 29345842
Ancevski Hunter K et al.PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.Mol Diagn Ther 22:1-10 (2018).
PubMed: 29119407
Yang L et al.Posttranscriptional Control of PD-L1 Expression by 17ß-Estradiol via PI3K/Akt Signaling Pathway in ERa-Positive Cancer Cell Lines.Int J Gynecol Cancer 27:196-205 (2017).
PubMed: 27870715
Oya Y et al.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.Oncotarget 8:103117-103128 (2017).
IHC
;
Human
.
PubMed: 29262550
Sato Y et al.The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.Pathol Int N/A:N/A (2017).
IHC-P, IF
;
Human
.
PubMed: 28139862
Remon J et al.Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.Lung Cancer 106:70-75 (2017).
PubMed: 28285697
Majzner RG et al.Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.Cancer 123:3807-3815 (2017).
PubMed: 28608950
Zhang M et al.Prognostic significance of PD-L1 expression and18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.Oncotarget 8:51630-51640 (2017).
IHC-P
;
Human
.
PubMed: 28881674
Fujimoto D et al.Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.Sci Rep 7:11373 (2017).
IHC
;
Human
.
PubMed: 28900290
Kim KJ et al.Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.Oncotarget 8:58887-58902 (2017).
IHC-P
;
Human
.
PubMed: 28938605
Scognamiglio T & Chen YT Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.Head Neck Pathol N/A:N/A (2017).
PubMed: 28948509
Miyazaki T et al.Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.J Neurooncol N/A:N/A (2017).
IHC
;
Human
.
PubMed: 28447277
Gambichler T et al.Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.Cancer Immunol Immunother N/A:N/A (2017).
PubMed: 28501937
Zhu J et al.Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.PLoS One 12:e0170879 (2017).
IHC-P
;
Human
.
PubMed: 28125702
Amaya CN et al.Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.Pathology 49:292-296 (2017).
IHC-P
;
Human
.
PubMed: 28238417
Chen S et al.PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.Int J Cancer 140:1384-1395 (2017).
IHC-P
;
Human
.
PubMed: 27925176
Jiao S et al.PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.Clin Cancer Res N/A:N/A (2017).
PubMed: 28167507
Badros A et al.Pembrolizumab, pomalidomide and low dose dexamethasone for relapsed/refractory multiple myeloma.Blood N/A:N/A (2017).
IHC
;
Human
.
PubMed: 28461396
Moon EK et al.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Ann Am Thorac Soc N/A:N/A (2017).
PubMed: 28613923
Bolognesi MM et al.Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections.J Histochem Cytochem 65:431-444 (2017).
PubMed: 28692376
Tsuchihashi K et al.Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.Mol Clin Oncol 6:665-668 (2017).
IHC-P
;
Human
.
PubMed: 28515919
Nakamura S et al.Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.PLoS One 12:e0186192 (2017).
IHC
;
Human
.
PubMed: 29049375
Huang Z et al.Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer.J Cancer 8:3190-3197 (2017).
IHC
.
PubMed: 29158791
Miao S et al.miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.Oncotarget 8:62143-62153 (2017).
PubMed: 28977933
Zhu J et al.Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.J Gynecol Oncol 28:e77 (2017).
PubMed: 29027395
Zhang Y et al.Genetic and immune features of resectable malignant brainstem gliomas.Oncotarget 8:82571-82582 (2017).
PubMed: 29137285
Rimm DL et al.A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.JAMA Oncol N/A:N/A (2017).
IHC
;
Human
.
PubMed: 28278348
He Y et al.PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.Med Sci Monit 23:1208-1216 (2017).
IHC
;
Human
.
PubMed: 28275222
Lazzari C et al.SECOND-LINE THERAPY OF SQUAMOUS NON-SMALL CELL LUNG CANCER: AN EVOLVING LANDSCAPE.Expert Rev Respir Med N/A:N/A (2017).
PubMed: 28467720
Pai SI & Faquin WC Programmed cell death ligand 1 as a biomarker in head and neck cancer.Cancer N/A:N/A (2017).
PubMed: 28472542
Ács B et al.PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.Breast 35:69-77 (2017).
IHC
;
Human
.
PubMed: 28651116
Brunnström H et al.PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.Mod Pathol N/A:N/A (2017).
IHC
;
Human
.
PubMed: 28664936
Connor AA et al.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.JAMA Oncol N/A:N/A (2016).
IHC-P
;
Human
.
PubMed: 27768182
Adam J et al.[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].Ann Pathol N/A:N/A (2016).
PubMed: 26778219
Lim SH et al.Pembrolizumab for the treatment of non-small cell lung cancer.Expert Opin Biol Ther N/A:N/A (2016).
PubMed: 26800463
Lee L et al.Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy.J Clin Pharmacol 56:157-69 (2016).
IHC
;
Human
.
PubMed: 26183909
Sun WY et al.Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.J Transl Med 14:173 (2016).
IHC
;
Human
.
PubMed: 27286842
Califano R et al.Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.Curr Oncol Rep 18:59 (2016).
PubMed: 27484062
Hutarew G PD-L1 testing, fit for routine evaluation? From a patholo?gist's point of view.Memo 9:201-206 (2016).
IHC
;
Human
.
PubMed: 28058063
Fan Y et al.Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.Onco Targets Ther 9:6075-6082 (2016).
IHC
;
Human
.
PubMed: 27785054
Jin Z & Yoon HH The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instabilityvs. PD-L1.J Gastrointest Oncol 7:771-788 (2016).
IHC
.
PubMed: 27747091
Phillips T et al.Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non-Small Cell Lung Cancer.Appl Immunohistochem Mol Morphol N/A:N/A (2015).
IHC
;
Human
.
PubMed: 26317305
Motzer RJ et al.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.J Clin Oncol 33:1430-7 (2015).
Human
.
PubMed: 25452452
D'Angelo SP et al.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.Hum Pathol 46:357-65 (2015).
IHC-P, IHC
;
Human
.
PubMed: 25540867
Gettinger SN et al.Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol 33:2004-12 (2015).
Human
.
PubMed: 25897158
Brahmer J et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.N Engl J Med 373:123-135 (2015).
IHC-P, IHC
;
Human
.
PubMed: 26028407
Rizvi NA et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.Lancet Oncol 16:257-65 (2015).
Human
.
PubMed: 25704439
Weber JS et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol 16:375-84 (2015).
Human
.
PubMed: 25795410
Robert C et al.Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 372:320-30 (2015).
Human
.
PubMed: 25399552
Larkin J et al.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med 373:23-34 (2015).
Human
.
PubMed: 26027431
Postow MA et al.Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med 372:2006-17 (2015).
Human
.
PubMed: 25891304
Gibney GT et al.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.Clin Cancer Res 21:712-20 (2015).
Human
.
PubMed: 25524312
Wolchok JD et al.Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med 369:122-33 (2013).
Human
.
PubMed: 23724867
Weber JS et al.Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.J Clin Oncol 31:4311-8 (2013).
Human
.
PubMed: 24145345
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Get resources and offers direct to your inboxSign up